Shanghai Medicilon Inc. (688202.SS)

37.64 -2.36 (-5.90%) At close: 03:00PM CST

Shanghai Medicilon Inc.

585 Chuanda Road
Shanghai 201299
China
86 21 5859 1500
https://www.medicilon.com.cn

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 2,600

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Chunlin Chen Ph.D.	Co-Founder, CEO & Executive Director	N/A	N/A	1962
Ms. Binbin Liu	Chief Financial Officer	N/A	N/A	1977
Mr. Shuangqing Peng Ph.D.	CSO & Head of Preclinical Research Department	N/A	N/A	1963
Dr. Jinna Cai Ph.D.	CBO, Deputy GM & Director	N/A	N/A	1965
Dr. Xuedong Dai Ph.D.	Executive Vice President of International R&D Department	N/A	N/A	1970

Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CNY.

Description

Shanghai Medicilon Inc., a drug discovery contract research organization, provides drug discovery and development services to pharmaceutical and biotechnology companies in China and internationally. It offers chemistry services, including medicinal, synthesis, and analytical chemistry services, as well as process development services; and drug formulation services, such as pre-formulation and analytical development services, as well as research on quality control and clinical trial material services. The company also provides biology services comprising recombinant protein, crystallization and structural, discovery biology, computational biology and molecular modeling, and kinase services, as well as prepackaged M9 selenomethionine growth media kits and packages for growing cell culture in IPTG-inducible bacterial expression systems. In addition, it offers pharmacology services, including cancer xenograft, metabolic disease, inflammation and immunological, neurological disorders, and other disease models; services in the areas of in vitro ADME and in vivo pharmacokinetics; and bioanalytical services, such as large and small molecule services. Further, the company provides preclinical services comprising preclinical pharmacokinetic and safety evaluation. Shanghai Medicilon Inc. was founded in 2004 and is headquartered in Shanghai, China.

Corporate governance

Shanghai Medicilon Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.